HOXB9 Antibody

1. These findings integrate the complexity of numerous mechanisms of anti-VEGF resistance into the single transcription factor HOXB9. Silencing HOXB9 could be a promising approach to modulate this resistance. Our results candidate HOXB9 as predictive biomarker for selecting colorectal cancer patients for antiangiogenic therapy PMID: 28298545
2. Study demonstrated that HOXB9 may facilitate hypertrophic scar formation via activating the mitogenactivated protein kinase signaling pathway. PMID: 28656236
3. this study revealed that HOXB9, HOXB13, and HOXD13 were upregulated and may play important roles in laryngeal squamous cell carcinoma (LSCC). Moreover, HOXB9 may serve as a novel marker of poor prognosis and a potential therapeutic target in LSCC patients. PMID: 28808656
4. These findings suggest that hoxb7 and hoxb9 proteins might play a role in salivary gland tumourigenesis, but in contrast to the reported for other human cancers, they were not significant prognostic determinants in the sample studied PMID: 26991799
5. HOXB9 interfered the activities of NF-kappaB, nuclear factor of activated T-cells (NFAT) and AP-1 but not retinoic acid receptor-related orphan receptor, resulting in attenuation of the production of selective cytokines in activated T cells. PMID: 26926958
6. AcK27-HOXB9 suppresses the transcription of its target gene Jumonji domain-containing protein 6 (JMJD6) by direct occupying the promoter of JMJD6 gene. PMID: 27613418
7. High expression of HoxB9 is a prognostic marker for lung adenocarcinoma patients. PMID: 25324169
8. We also found that FAT10 may act its oncogenic functions through regulating HOXB9. Collectively, the results suggested that FAT10 may be a novel therapeutic target for osteosarcoma patients PMID: 27279480
9. the results of the present study suggested that HOXB9 is a tumor suppressor in gastric carcinoma, and its activity was controlled by different regulatory mechanisms such as the hexapeptide motif as a "brake" in this case PMID: 26536658
10. Expression of GalNAc-T14 or HOXB9 was strongly correlated with reduced recurrence-free survival in lung adenocarcinomas. PMID: 26544896
11. Knock-down of HOXB9 expression decreased migration, invasion and proliferation but did not alter adhesion. PMID: 25860510
12. HOXB9 promotes epithelial-to-mesenchymal transition via TGF-beta1 pathway in hepatocellular carcinoma cells. PMID: 25081022
13. Identification of the transcription factor binding site of the HOXB9 promoter region suggests that E2F1 is a direct regulator of HOXB9 expression in breast cancer. PMID: 25136922
14. Low HOXB9 expression promotes pancreatic ductal adenocarcinoma progression. PMID: 25724625
15. HOXB9 promoted colon adenocarcinoma differentiation. PMID: 25025961
16. HOXB9 overexpression increased the tumorigenicity of glioma cells in vivo. Moreover, the activation of transforming growth factor-beta1 contributed to HOXB9-induced oncogenic activities. PMID: 24582746
17. Data show that the HOXB9 overexpression group had significantly shorter overall survival time than the HOXB9 downexpression group. PMID: 24462859
18. rs2303486 may be associated with severity of developmental dysplaasia of the hip in Chinese Han females. PMID: 24600698
19. HOXB9 is down-regulation in gastric carcinoma and may be a novel prognostic marker for poorer clinical outcome for patients with gastric carcinoma. PMID: 23332081
20. The expression of HOXB9, its relationship to clinical factors in breast cancer and efficacy as a prognostic factor were discussed. PMID: 23350386
21. HOXB9 is overexpressed in breast cancer tissue. PMID: 22863320
22. reduced expression of CD56 is associated with homeobox B9 in papillary thyroid carcinomas. Further, silencing of homeobox B9 is more common in older age and is linked to extrathyroidal extension and advanced pathologic stage of papillary thyroid carcinoma PMID: 22225776
23. HOXB9 overexpression promoting tumor cell proliferation and angiogenesis is associated with breast cancer. PMID: 22396001
24. The effect of HOXB9 on the response to ionizing radiation requires the baseline ATM activity before irradiation and epithelial-to-mesenchymal transition induced by TGF-beta. PMID: 21930940
25. HOXB9 is an E2-responsive gene and ERs coordinate with MLL1 and MLL3 in E2-mediated transcriptional regulation of HOXB9. PMID: 21428455
26. deregulated expression of HOXB9 contributes to breast cancer progression and lung metastasis by inducing several growth factors that alter tumor-specific cell fates and the tumor stromal microenvironment PMID: 20080567
27. ERK5 probably mediates HOXB9 expression by repressing BMI1 in Hodgkin lymphoma cell lines PMID: 17148583
28. Two WNT target genes, LEF1 and HOXB9, are identified as promoters of lung adenocarcinoma metastasis and mediators of chemotactic invasion and colony outgrowth. PMID: 19576624

显示更多

收起更多

HGNC: 5120

OMIM: 142964

KEGG: hsa:3219

STRING: 9606.ENSP00000309439

UniGene: Hs.463350